A Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2012

At a glance

  • Drugs Retaspimycin (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Aug 2011 Patient number was reported as 23, according to an Infinity Pharmaceuticals Quarterly Report.
    • 10 Jun 2011 Planned end date changed from 1 Feb 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top